Recent news coverage includes general market and sector news with limited direct updates on CytoDyn. Notably, CytoDyn secured funding to launch an Expanded Access Program for leronlimab in breast cancer and appointed key consultants in oncology and hepatology in prior periods.

• CytoDyn secured funding to launch an Expanded Access Program for leronlimab in breast cancer patients who have exhausted other treatment options [N15].
• The company appointed Richard Pestell as lead consultant in oncology and Melissa Palmer as lead consultant in hepatology, indicating focus on clinical expertise [N16][N17].
• No recent direct news on clinical trial results or regulatory approvals was reported in the latest news batch.
• Recent broader market news includes profit declines and milestone deals in the biotech sector but does not directly pertain to CytoDyn [N1][N2][N3].

CytoDyn's leronlimab has demonstrated potential in inhibiting cancer metastasis and modulating immune responses, supported by preclinical and early clinical data. The completion of enrollment in the Phase 2 colorectal cancer study and initiation of Expanded Access Programs indicate progress in clinical development. Collaborations with partners like Natera for advanced molecular analyses may provide valuable insights to optimize development. The company's efforts to develop longer-acting formulations could improve patient convenience and commercial appeal. These factors contribute to the potential for leronlimab to become a differentiated therapeutic option in oncology [S1].

CytoDyn faces significant risks including its current financial position with limited cash reserves and a current ratio below 1, indicating liquidity constraints. The company has reported substantial net losses and increased operating expenses related to clinical trials. Its ability to continue operations depends on raising additional capital, which may result in dilution to existing shareholders. Clinical development outcomes remain uncertain, and regulatory approvals are not guaranteed. Failure to secure funding or achieve positive clinical results could impair the company's ability to advance leronlimab and sustain operations [S2].

CytoDyn's potential competitive advantage lies in its proprietary monoclonal antibody leronlimab, which targets the CCR5 receptor implicated in cancer metastasis and immune regulation. The drug's unique mechanism as a competitive inhibitor with target specificity differentiates it from other CCR5 antagonists. The company holds patents and pursues ongoing patent protection to safeguard its intellectual property. Its clinical development focus on multiple solid tumor indications and strategic collaborations may enhance its position. However, as a clinical-stage biotech, its moat depends on successful clinical validation and regulatory approvals [S1].

• Capital Raising Risk: CytoDyn requires significant additional funding to continue clinical development and operations. There is no assurance that future funding will be available on acceptable terms or at all, which could impact the company's ability to continue as a going concern [S2].
• Clinical Development Risk: The success of leronlimab depends on clinical trial outcomes in multiple indications. Delays, negative results, or inability to demonstrate safety and efficacy could hinder regulatory approvals and commercialization [S1].
• Regulatory Risk: Obtaining FDA and other regulatory approvals involves uncertainties. Changes in regulatory requirements or failure to meet endpoints could delay or prevent market access [S1].
• Liquidity Risk: As of August 31, 2026, the company had a current ratio of 0.38 and cash ratio of 0.33, indicating potential liquidity challenges to meet short-term obligations [S2].
• Dilution Risk: Future equity or convertible debt financings may dilute existing shareholders and could include terms that restrict company operations [S2].

• CytoDyn Inc. is a clinical-stage biotechnology company focused on the clinical development of leronlimab, a humanized monoclonal antibody targeting the CCR5 receptor, for multiple therapeutic indications including solid-tumor oncology [S1].
• Leronlimab is being studied in Phase 2 clinical trials for relapsed/refractory microsatellite stable metastatic colorectal cancer (CLOVER study) and metastatic triple-negative breast cancer (mTNBC) [S1].
• The company completed enrollment in the CLOVER Phase 2 study with over 60 patients across multiple U.S. clinical sites as of April 2026 [S1].
• CytoDyn has initiated an Expanded Access Program (EAP) for triple-negative breast cancer patients who have exhausted other treatment options, providing access to leronlimab outside clinical trials [S1].
• The company collaborates with Natera, Inc. to analyze clinical trial samples and real-world data to guide development strategies for leronlimab in colorectal cancer and other solid tumors [S1].
• Preclinical and clinical data suggest leronlimab may inhibit CCR5-mediated cancer cell metastasis, modulate immune responses, and potentially enhance chemotherapy and immune checkpoint inhibitor efficacy [S1].
• CytoDyn is pursuing clinical development in glioblastoma multiforme (GBM) with preclinical studies and plans for pilot clinical studies [S1].
• The company is developing longer-acting CCR5 antagonist formulations through a joint development agreement using generative AI drug discovery tools [S1].
• As of August 31, 2026, CytoDyn had approximately $16.4 million in cash and cash equivalents, current assets of $18.98 million, and current liabilities of $49.7 million, resulting in a current ratio of 0.38 and a cash ratio of 0.33 [S2].
• The company reported a net loss of approximately $19.9 million for the three months ended August 31, 2026, with increased operating expenses driven by clinical trial activities and stock-based compensation [S2].
• CytoDyn finances its operations primarily through equity and convertible debt issuances, with approximately 118.5 million shares of common stock available for issuance as of August 31, 2026 [S2].
• The company faces risks related to its ability to raise additional capital, regulatory approvals, clinical trial outcomes, and potential dilution of shareholders [S2].